"When drug companies won't sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less," White House National Economic Advisor Lael Brainard said during a press call.
Opponents say march-in rights were never meant for tackling high prices. They say the Bayh-Dole Act is critical for public research and innovation.
#Prescription drug prices #Biden administration #March-in rights #Taxpayer-funded drugs #Bayh-Dole Act
[
Collection
]
[
|
...
]